Farr Miller & Washington’s Teva Pharmaceuticals TEVA Stock Holding History

Farr Miller & Washington’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,600	Closed	-$203K	–	154
2016 Q4	$203K	Hold	5,600	–	–	0.02%	140
2016 Q3	$257K	Hold	5,600	–	–	0.03%	114
2016 Q2	$281K	Hold	5,600	–	–	0.03%	107
2016 Q1	$300K	Hold	5,600	–	–	0.03%	102
2015 Q4	$368K	Hold	5,600	–	–	0.04%	93
2015 Q3	$316K	Hold	5,600	–	–	0.04%	96
2015 Q2	$331K	Hold	5,600	–	–	0.04%	102
2015 Q1	$349K	Hold	5,600	–	–	0.04%	99
2014 Q4	$322K	Hold	5,600	–	–	0.04%	102
2014 Q3	$301K	Sell	5,600 -67	-1%	-$3.55K	0.04%	96
2014 Q2	$297K	Buy	5,667 +67	+1%	+$3.42K	0.04%	112
2014 Q1	$296K	Hold	5,600	–	–	0.04%	97
2013 Q4	$224K	Hold	5,600	–	–	0.03%	116
2013 Q3	$212K	Hold	5,600	–	–	0.03%	115
2013 Q2	$220K	Buy	+5,600	New	+$218K	0.04%	113

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Farr Miller & Washington's TEVA Position: Q1 2017 in Review

Farr Miller & Washington sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 5,600 shares — an estimated $203K sold.

Farr Miller & Washington first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $368K in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Farr Miller & Washington reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Farr Miller & Washington sold 5,600 Teva Pharmaceuticals shares in Q1 2017, an estimated $203K.
Farr Miller & Washington first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Farr Miller & Washington's Teva Pharmaceuticals position peaked at $368K in Q4 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Farr Miller & Washington's 13F filing for Q1 2017, filed 12 May 2017.